Servier is an independent Group governed by a non-profit foundation, with our headquarters in France (Suresnes). Operating in 150 countries, we have 22,000 employees worldwide. Entirely independent, we invest each year an average of 25% of our total revenue, excluding generic activities, into Research and Development, and all profits are used for further development. Our R&D is focused on five main therapeutic areas:

▪ Cardio metabolic and vascular diseases
▪ Cancer
▪ Neuropsychiatric diseases
▪ Immune-inflammatory diseases

We have long been a leader in the field of cardiology, and we aim to secure a place of prominence in the area of immune-inflammatory diseases. We have 16 chemical and pharmaceutical manufacturing centers worldwide which produce more than 600 million boxes of medicines, each year. We have been committed to therapeutic progress to serve patient needs with the help of healthcare professionals. We strive to transmit to future generations a world that can ensure access to quality health care for all. Traditionally, Servier is a worldwide market leader on hypertension, cardiology, diabetology and venous diseases, but recently the emphasis has shifted to include research in oncology and haematology with innovative targeted treatments to address high unmet medical needs. Servier Bulgaria has been present in the Bulgarian market since 1993 with a team of 77 employees and 43 registered medicaments. Servier Bulgaria has built strong partnerships over those 32 years with scientific leaders, healthcare providers and patient associations in its fields. Servier Bulgaria is also dedicated to leaving a positive and sustainable impact on society and environment.